Apr. 7 at 10:22 PM
$SXTP
Another thing to know: The company effected a 1-for-4 reverse split effective January 20, 2026, after already having done a 1-for-5 reverse split in February 2025 and a 1-for-12 reverse split in August 2024.
As for Nasdaq risk, that was serious but improved. SXTP got a delisting notice in January 2026 over the minimum bid-price rule, but on February 11, 2026 Nasdaq told the company it had regained compliance, cancelled the hearing, and the matter was closed.
So my honest read is:
Amazon Pharmacy listing: real, but not a game-changing new catalyst by itself.
Best bull case: approved product + expanded access channels + positive babesiosis signals.
Biggest risks: tiny revenue base, ongoing losses, dilution/financing pressure, reverse-split history.
Recently the stock has been trading under
$2, around
$1.7–
$1.8 based on April 2026 quote pages, which fits the profile of an ultra-small, headline-driven trader rather than a stable investment.
